Do clinical trial data suggest a role for SGLT2-inhibitors in primary prevention of heart failure and chronic kidney disease?

Staessen, Jan A; Janssens, Stefan; Van de Werf, Frans

Staessen, Jan A; Janssens, Stefan; Van de Werf, Frans.

Afiliación

Staessen JA; Research Institute Alliance for the Promotion of Preventive Medicine, Belgium.
Janssens S; Biomedical Science Group, Faculty of Medicine, University of Leuven, Leuven, Belgium.
Van de Werf F; Division of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Int J Cardiol Cardiovasc Risk Prev ; 10: 200100, 2021 Sep.

Article en En | MEDLINE | ID: mdl-35112113

Palabras clave

Chronic kidney disease; Diastolic left ventricular dysfunction; Heart failure; Prevention; SGLT2 inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Cardiol Cardiovasc Risk Prev Año: 2021 Tipo del documento: Article País de afiliación: Bélgica Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google